Abstract:To study the influence of dopaminergic activity on the expression of dopamine D-2 receptors and glutamic acid decarboxylase in substantia nigra, mice were treated daily for several days with an irreversibly acting dopamine D-1 and dopamine D-2 receptor antagonist N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ) or with a selective irreversible D-2 dopamine receptor antagonist fluphenazine-N-mustard. Mice were killed 24 h after the last injection. dopamine D-1 and dopamine D-2 receptors were determined by receptor autoradiography, and dopamine D-1 and dopamine D-2 receptor mRNA and glutamic acid decarboxylase mRNA were determined by in situ hybridization histochemistry. The results showed that treatment with EEDQ, which blocked 80% to 85% of the dopamine D-2 and dopamine D-1 receptors in substantia nigra, increased the levels of dopamine D-2 receptor mRNA in substantia nigra by about 27%. Treatment with fluphenazine-N-mustard, which blocked about 85% of the dopamine D-2 receptors in substantia nigra but had no significant effect on dopamine D-1 receptors, increased the levels of dopamine D-2 receptor mRNA about 34%. There were no detectable levels of dopamine D-1 receptor mRNA in substantia nigra either in control animals or in animals treated with the dopamine receptor antagonists. Glutamic acid decarboxylase mRNA was expressed in several regions of the mid-brain but only that expressed in substantia nigra was altered by treatment with dopamine receptor antagonist. The levels of glutamic acid decarboxylase mRNA in substantia nigra increased by 83% following EEDQ treatment, and by 50% following treatment with fluphenazine-N-mustard. These results suggested that dopamine receptors, particularly dopamine D-2 receptors, play an important role in regulating the expression of both dopamine D-2 receptor mRNA and glutamic acid decarboxylase mRNA in substantia nigra.

Dopamine-Receptor Blockade Increases Dopamine D-2 Receptor And Glutamic-Acid Decarboxylase Messenger-Rnas In Mouse Substantia-Nigra